글로벌 급성 림프구성/림프모구암(ALL) 치료제 시장 – 2030년까지의 산업 동향 및 예측

급성 림프구성/림프모구암(ALL) 치료제 시장 분석 및 규모

치료용 제품 승인 급증은 시장 성장을 가속화하는 중요한 요인이며, 질병에 대한 인식을 확산하기 위한 정부 및 제약 기관의 이니셔티브 증가, 제조업체의 투자 증가로 인해 발생한 질환 치료 기술의 발전 증가, 신제품 승인 수의 증가는 급성 림프구성/림프모구암(ALL) 치료제 시장을 주도하는 주요 요인입니다. 또한 의료 기기의 기술적 발전 및 현대화 증가, 의료 부문의 연구 개발 활동 증가, 신흥 시장이 증가함에 따라 2023년에서 2030년 사이에 급성 림프구성/림프모구암(ALL) 치료제 시장에 새로운 기회가 창출될 것입니다.

Data Bridge Market Research는 2022년에 25억 3천만 달러였던 글로벌 급성 림프구성/림프모구암(ALL) 치료제 시장이 2030년까지 38억 8천만 달러로 급증할 것으로 분석했으며, 2023년에서 2030년까지 예측 기간 동안 5.25%의 CAGR을 기록할 것으로 예상합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

급성 림프구성/림프모구암(ALL) 치료제 시장 범위 및 세분화

시장 정의

급성 림프구성/림프모구백혈병(ALL) 치료제는 급성 림프구성/림프모구백혈병(주로 백혈구에 영향을 미치는 혈액암의 한 유형)과 싸우기 위한 제약 제품 및 치료법을 개발, 생산, 유통하는 사업 부문입니다.

글로벌 급성 림프구성/림프모구암(ALL) 치료제 시장 역학

운전자

• 노령 인구 증가

글로벌 헬스케어 산업의 원동력 중 하나는 고령화 인구의 증가입니다. 세계 인구가 계속 고령화됨에 따라 의료 치료, 장기 요양 및 의약품을 포함한 헬스케어 서비스에 대한 수요가 증가하고 있습니다. 노인은 연령 관련 질병 및 만성 질환으로 인해 더 많은 헬스케어 서비스가 필요한 경우가 많으며, 이는 헬스케어 부문의 전반적인 성장을 촉진합니다. 이러한 인구 통계적 추세는 헬스케어 제공자와 제약 회사가 노인 인구의 헬스케어 요구를 충족할 수 있는 기회를 제공합니다.

• 의료 분야의 기술적 발전

Technological advancements in healthcare are a significant driver for the industry. Innovations such as telemedicine, wearable health devices, artificial intelligence (AI) in diagnostics, and robotic surgery have improved patient care, efficiency, and accuracy in diagnosis and treatment. These technologies not only enhance the patient experience but also contribute to cost savings and improved outcomes. Healthcare organizations that invest in and adopt these technologies can gain a competitive edge and provide higher-quality care to their patients

Opportunity

• Personalized Medicine and Biomarker Development

A promising opportunity in the ALL therapeutics market is the advancement of personalized medicine and the development of biomarkers. Personalized medicine involves tailoring treatment strategies to individual patients based on their genetic, genomic, and molecular profiles. In the case of ALL, identifying specific genetic mutations or biomarkers that drive the disease can enable oncologists to select the most appropriate and effective treatment for each patient

The development of biomarkers for ALL can help in early diagnosis, prognosis prediction, and treatment response monitoring. Companies that invest in research to identify relevant biomarkers and develop diagnostic tests can create valuable tools for clinicians and contribute to the growth of personalized treatment approaches 

Restraint/Challenge

• Healthcare Regulatory Challenges

One major restraint in the healthcare industry is the complex and ever-changing regulatory landscape. Healthcare regulations vary from country to country and can be subject to frequent updates. Complying with these regulations requires significant resources, including legal expertise, documentation, and adherence to strict standards of care. Navigating regulatory challenges can be time-consuming and costly for healthcare providers and pharmaceutical companies, potentially slowing down the development and delivery of new treatments and services. This regulatory burden can act as a constraint on the growth and innovation within the healthcare industry

This acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Developments

• In August 2023, Genmab A/S announced that on September 12, 2023, at 3:35 PM EDT/9:35 PM CEST, its Chief Executive Officer Jan van de Winkel, Ph.D., and Chief Financial Officer Anthony Pagano will take part in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference.  A webcast of the event will be available, and it will feature brief opening remarks and a round of questions and answers
• In July 2023, the introduction of PERCLOT Absorbable Hemostatic Powder in the U.S. was announced by Baxter International Inc., a leader in advancing surgical innovation worldwide. For patients with intact coagulation, PERCLOT is a passive, absorbable hemostatic powder that is ready to use and intended to stop minor bleeding

Impact and Current Market Scenario of Raw Material Shortage and Shipping Delays

Data Bridge Market Research offers a high-level analysis of the market and delivers information by keeping in account the impact and current market environment of raw material shortage and shipping delays. This translates into assessing strategic possibilities, creating effective action plans, and assisting businesses in making important decisions.

Apart from the standard report, we also offer in-depth analysis of the procurement level from forecasted shipping delays, distributor mapping by region, commodity analysis, production analysis, price mapping trends, sourcing, category performance analysis, supply chain risk management solutions, advanced benchmarking, and other services for procurement and strategic support.

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Scope

The global acute lymphocytic/lymphoblastic leukemia (ALL) Therapeutics Market is segmented on the basis of age group, diagnosis, drug type, therapy, cell type, and route of administration. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Age Group

• Pediatrics
• Adults

 Diagnosis

• Biopsy and Bone Marrow Aspiration
• Complete Blood Count (CBC) and Differential
• Presence of Philadelphia Chromosome
• Spinal Tap and Cerebrospinal Fluid (CSF) Analysis
• Immunophenotyping/Phenotyping
• Flow Cytometry
• Polymerase Chain Reaction (PCR)

Drug Type

• Existing Drugs
• Pipeline Drugs

Therapy

• Targeted Drugs and Immunotherapy
• Chemotherapy
• Radiation Therapy
• Stem Cell Transplantation
• Pipeline

Cell Type

• Philadelphia Chromosome
• Precursor B-Cell ALL
• T-Cell ALL

Route of Administration

• Oral
• Parenteral

Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Regional Analysis/Insights

The acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is analyzed and market size insights and trends are provided by age group, diagnosis, drug type, therapy, cell type and route of administration as referenced above.

The countries covered in the global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa

North America dominates and register the highest growth rate in the acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market due to rise in the surge in the approvals of products for the treatment and rise in the initiatives taken by the government and pharmaceutical organizations to spread awareness regarding the disease in this region.

Asia-Pacific is the expected region in terms of growth in acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market due to rise in the prevalence of acute lymphocytic/lymphoblastic leukemia (ALL) in this region.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the Market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share Analysis

급성 림프구성/림프모구암(ALL) 치료제 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 위에 제공된 데이터 포인트는 급성 림프구성/림프모구암(ALL) 치료제 시장과 관련된 회사의 초점에만 관련됩니다.

급성 림프구성/림프모구백혈병(ALL) 치료제 시장에서 활동하는 주요 업체는 다음과 같습니다.

• 암젠 주식회사(미국)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 에리텍파마(프랑스)
• 노바티스 AG(스위스)
• 파이저 주식회사(미국)
• Rare Disease Therapeutics, Inc. (미국)
• 사노피(프랑스)
• 스펙트럼 파마슈티컬스(미국)
• 다케다제약 주식회사(일본)
• 젠맙 A/S(덴마크)
• 백스터(미국)
• 길리드 사이언스 주식회사(미국)
• 셀진 코퍼레이션(미국)
• 에자이 주식회사(일본)
• 심바이오제약(일본)
• Kiadis Pharma(네덜란드)
• OBI Pharma(대만)
• 아스텔라스파마 주식회사(일본)
• Medexus Pharma, Inc. (캐나다)

SKU-43604